Investors
Genomic Vision is a publicly-traded company on the Euronext regulated market in Paris
Press Releases
2021
29/07/2021: First-half 2021 results
10/06/2021: 2nd call for OGM on June 30, 2021
17/05/2021: Financial Information for the First Quarter of 2021
14/05/2021: Partnership with SANOFI
29/04/2021 : Financial information: Annual Results 2020
14/04/2021 : Appointment of Mark David Lynch as Global Commercial and Marketing Director
18/02/2021 : Financial Information for the Fourth Quarter of 2020
12/01/2021 : French documentation “Bilan Semestriel du contrat de liquidité S2 2020”
2020
24/11/2020 : Issuance of the first tranche of convertible notes with warrants (OCABSA)
12/11/2020 : Financial Information for the Third Quarter of 2020
13/10/2020 : Genomic Vision signs a distribution agreement for Covid-19 rapid diagnostic tests with Toda Pharma
29/09/2020 : First Half Results
22/09/2020 : Genomic Vision: convening of another Extraordinary General Meeting on October 30, 2020
24/07/2020 : Genomic Vision: convening of a new Combined Shareholders’ Meeting on August 10, 2020
20/07/2020 : Financial Information for the First Half of 2020
09/07/2020 : Half-yearly balance of the Liquidity Agreement with CM-CIC Securities
06/07/2020 : Press release on the availability of the 2019 annual financial report
06/07/2020 : Press release on the availability of the preparatory documents for the AGM of 24 July 2020
29/05/2020: Financial information for the 1st quarter of 2020
21/05/2020: Financial information: FYR 2019
18/05/2020 : Financial information : Drawdown of the 4th tranche
30/04/2020 : Financial information
09/04/2020 : Genomic Vision strenghtens its governance
13/02/2020 : Dana Farber Cancer Institute adopts Genomic Vision’s platform including the FiberVisionS
11/02/2020 : Financial information
30/01/2020 : Q4 2019 Financial information
21/01/2020 : Genomic Vision’s technology to be tested by the NIST
15/01/2020 : Strategic Partnership between Genomic Vision and GIPTIS
2019
30/10/2019 : Q3 2019 Financial information
21/10/2019 : Promising results for the TLA assay
25/10/2019 : Genomic Vision’s platform installed at the NIH
24/09/2019 : Financial information for the First Half of 2019
26/07/2019 : Financial information for the First Half of 2019: turnover and cash position
22/07/2018 : Bilan semestriel du contrat de liquidité contracté avec CM-CIC Securities (in French)
09/07/2019 : Genomic Vision reports of the Combined Shareholders’ Meeting of July 8, 2019
21/06/2019 : Second convening of Shareholders meeting of July 8, 2019
02/05/2019: Financial information for the First Quarter of 2019
26/03/2019 : Genomic Vision announces the signing of the financing contract with Winance
06/03/2019 : 2018 Annual Results
18/02/2019 : Genomic Vision: convening of another Extraordinary Shareholders’ Meeting on March 4, 2019
08/02/2019 : Genomic Vision: Oxford University selects the molecular combing technology to study DNA replication in the context of a rare disease
06/02/2019 : Financial information for the Fourth Quarter of 2018
11/01/2019 : Bilan semestriel du contrat de liquidités contracté avec CM-CIC Securities (in French)
2018
22/11/2018 : Genomic Vision signs a licensing agreement with Phyteneo on HPV integration test in Czech Republic
29/10/2018 : Genomic Vision: positive results of the clinical study EXPL-HPV-002 in cervical cancer detection
24/10/2018 : Financial information for the Third Quarter of 2018
28/09/2018 : First Semester Financial Report 2018 (in French)
10/09/2018 : Genomic Vision achieves second milestone with Quest Diagnostics on SMA carrier testing
09/08/2018
Genomic Vision and European Equity Partners enter into agreement to use molecular combing as a genome integrity assay in the field of biomanufacturing
06/08/2018
Genomic Vision: new perspectives in the genomic analysis of plants
06/08/2018
Genomic Vision: new perspectives in the genomic analysis of plants
25/07/2018
First half 2018 results
17/07/2018
Bilan semestriel du contrat de liquidité contracté avec CM-CIC Securities (in French)
05/07/2018
Genomic Vision provides an update on its commercial development and financial situation
19/06/2018
Compte rendu de l’assemblée générale mixte du 19 juin 2018 (in French)
11/06/2018
Genomic Vision: the performances of the FSHD diagnostic assay presented at the 2018 International FSHD Research Conference (IRC) in Las Vegas
29/05/2018
All documents for the shareholders’ meeting of June 19, 2018 are available on Genomic Vision website (in French only)
16/05/2018
Genomic Vision enters into a strategic research collaboration with Children’s Medical Research Institute (CMRI) on telomere length assay
02/05/2018
Genomic Vision invited to present molecular combing at Genopole
27/04/2018
Financial Information for the First Quarter of 2018
26/04/2018
Provision of the 2017 Financial Annual Report (in French only)
24/04/2018
Genomic Vision invited to present FiberVision platform at the Nist-FDA Genome Editing workshop in Gaithersburg (Maryland)
21/03/2018
2017 Annual Results
14/03/2018
Genomic Vision extends its collaboration with Quest Diagnostics in spinal muscular atrophy (SMA)
17/01/2018
2017 Annual revenue from sales: +36% to €2.1 million
04/01/2018
Bilan semestriel du contrat de liquidité contracté avec CM-CIC Securities (in French only)
19/12/2017
Genomic Vision optimizes the terms of its OCABSA (Convertible Notes with Warrants) financing line to obtain greater flexibility within the framework of its development
13/11/2017
All documents for the shareholders’ meeting of December 4, 2017 are available on Genomic Vision website (in French only)
24/10/2017
Financial information at Sept 30, 2017
19/10/2017
Genomic Vision signs a distribution agreement with AmCare Genomics Laboratory in China for its FSHD diagnostic assay
18/10/2017
Genomic Vision: report of the LSR R&D Day on october 16, 2017
11/10/2017
Genomic Vision presented the interim results of its clinical trial in cervical cancer screening at the Eurogin annual congress
03/10/2017
Genomic Vision hosts 2nd R&D day on october 16th in Paris
13/09/2017
High attendance at the first US satellite symposium on molecular combing
27/07/2017
Molecular combing featured in an oral presentation on CRISPR/Cas9 gene editing at the 3rd CSHL meeting in New York
25/07/2017
First half 2017 results
12/07/2017
The Cologne Center for Genetics (CCG), a major European core facility in genetic analyis, adopts the molecular combing technology
27/06/2017
Genomic Vision launches its online store “GV Store”
20/06/2017
Compte rendu de l’assemblée générale mixte du 20 juin 2017 (in French)
19/06/2017
Genomic Vision inks Chinese distribution deal with APG Bio Ltd
30/05/2017
All documents for the shareholders’ meeting of June 20, 2017 are available on Genomic Vision website (in French only)
30/05/2017
Genomic Vision declares its eligibility to the French tax regime PEA-PME for 2017/2018 (in French only)
22/05/2017
Genomic Vision to enter into technological collaboration with AstraZeneca in oncology
15/05/2017
Report of the IVD R&D Day of 10 May 2017
10/05/2017
Genomic Vision announces promising preliminary results for its clinical study in cervical cancer detection
09/05/2017
Financial information at March 31, 2017
20/04/2017
Genomic Vision hosts inaugural R&D day with its long-standing partner Quest Diagnostics
29/03/2017
Issuance of all the warrants for convertible notes with warrants (BEOCABSA)
01/03/2017
2016 annual results in line with the successful execution of the new strategy in LSR market
09/01/2017
Financial information at December 31st, 2016
28/10/2016
Financial information at September 30, 2016 and implementation of a flexible financing via the reserved issuance of convertible notes with warrants
20/10/2016
Genomic Vision Presents the Initial Results of the Pilot Study Undertaken with Quest Diagnostics in Spinal Muscular Atrophy (SMA) at the ASHG 2016 Annual Meeting in Vancouver or the first half of 2016
26/07/2016
Results for the first half of 2016
20/07/2016
Genomic Vision is accelerating its clinical trial in cervical cancer with an additional study in the Czech Republic
11/07/2016
Genomic Vision launches EasyScan, the first digital service for analyzing DNA by molecular combing
16/06/2016
The clinical trial led by Genomic Vision and Reims University Hospital presented at the Eurogin Congress
09/05/2016
Financial information at March 31, 2016
23/03/2016
New strategic development area
22/03/2016
2015 Annual Results
17/03/2016
Genomic Vision obtains NF EN ISO 13485:2012 quality certification
10/03/2016
Genomic Vision’s DNA analysis technology singled out in a study published by Nature
08/02/2016
Genomic Vision to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference
04/02/2016
2016 Financial Calendar
18/01/2016
2015 sales in line with expectations after all planned milestones with Quest Diagnostics were met
14/01/2016
Genomic Vision to demonstrate ‘molecular combing’ technology’s ability to identify novel cancer-causing BRCA gene variants
11/01/2016
Genomic Vision Expands its Senior Management Team through a Number of Strategic Recruitments
14/12/2015
Genomic Vision and Reims University Hospital Launch Clinical Study to Establish New Screening Tool for Early Detection and Prevention of Cervical Cancer
03/12/2015
Genomic Vision signs a strategic partnership with the Imagine Institute, the largest European genetic research and care cluster
01/12/2015
GENOMIC VISION to Present at the LD Micro Main Event
12/11/2015
GENOMIC VISION to Present at the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum
22/10/2015
Revenue from 3rd quarter activity up 47%
15/10/2015
GENOMIC VISION and ROUEN University Hospital launch a trial to improve genetic counseling for Infantile Spinal Muscular Atrophy in France
31/07/2015
2015 first-half results in line with company expectations
09/06/2015
Genomic Vision selected for the Horizon 2020 program’s ‘BeyondSeq’ project with a total grant of €6 million
06/05/2015
Financial information of the 31st of March 2015 (French)
30/04/2015
2014 Financial Report available (French)
31/03/2015
Genomic Vision reaffirms its eligibility for the PEA-SME status for 2015/2016 (French)
15/03/2015
2014 annual results in line with the Company’s buoyant development
Total revenue from activity: €4.9 million
Operating costs under control
Solid cash position of €22.8 million
17/02/2015
Genomic Vision renews its Strategic Collaboration with Quest Diagnostics for three more years
09/02/2015
Financial Agenda 2015
15/01/2015
2014 Annual Revenue from Sales at €3.5 Million
07/01/2015
Genomic Vision achieves major milestone with delivery of new high-throughput genome analyzer to Quest Diagnostics
